{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:39:42Z","timestamp":1792075182461,"version":"4.4.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.eururo.2014.11.039","type":"journal-article","created":{"date-parts":[[2014,12,6]],"date-time":"2014-12-06T01:08:22Z","timestamp":1417828102000},"page":"386-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":246,"title":["Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Cecilia","family":"Bosco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsolt","family":"Bosnyak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Malmberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Adolfsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Van Hemelrijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.11.039_bib0005","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0022-5347(02)80307-X","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"167","author":"Huggins","year":"2002","journal-title":"J Urol"},{"issue":"Suppl 7","key":"10.1016\/j.eururo.2014.11.039_bib0010","first-page":"S3","article-title":"Hormonal therapy in prostate cancer: historical approaches","volume":"6","author":"Crawford","year":"2004","journal-title":"Rev Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2014.11.039_bib0020","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.2007.14.9021","article-title":"Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer","volume":"26","author":"Horwitz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0025","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2007.09.002","article-title":"European Association of Urology. EAU guidelines on prostate cancer","volume":"53","author":"Heidenreich","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0030","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.11.039_bib0035","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2009.1137","article-title":"Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease\u2013induced congestive heart failure or myocardial infarction","volume":"302","author":"Nanda","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.11.039_bib0040","doi-asserted-by":"crossref","unstructured":"Ziehr DR, Chen M, Zhang D, et al. Association of androgen deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. BJU Int. In press. http:\/\/dx.doi.org\/10.1111\/bju.12905","DOI":"10.1111\/bju.12905"},{"key":"10.1016\/j.eururo.2014.11.039_bib0045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0050","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1200\/JCO.2010.29.1567","article-title":"Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"28","author":"Van Hemelrijck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0055","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","article-title":"Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden","volume":"11","author":"Van Hemelrijck","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0060","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0065","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.11.039_bib0070","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1016\/j.eururo.2011.08.041","article-title":"Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer","volume":"60","author":"Azoulay","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0075","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2013.02.002","article-title":"Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study","volume":"65","author":"Jespersen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0080","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","article-title":"Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism","volume":"61","author":"Hu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0085","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","article-title":"Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care","volume":"34","author":"Mart\u00edn-Merino","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.eururo.2014.11.039_bib0090","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/PRS.0b013e318219c171","article-title":"The levels of evidence and their role in evidence-based medicine","volume":"128","author":"Burns","year":"2011","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.eururo.2014.11.039_bib0095","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1001\/jama.2011.1791","article-title":"Androgen deprivation therapy and competing risks","volume":"306","author":"Kelly","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2014.11.039_bib0100","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1056\/NEJM200006223422506","article-title":"A comparison of observational studies and randomized, controlled trials","volume":"342","author":"Benson","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.11.039_bib0105","unstructured":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklists. STROBE Statement Web site. http:\/\/www.strobe-statement.org\/index.php?id=available-checklists."},{"key":"10.1016\/j.eururo.2014.11.039_bib0110","unstructured":"Cardiovascular diseases (CVDs). World Health Organization Web site. http:\/\/www.who.int\/mediacentre\/factsheets\/fs317\/en\/."},{"key":"10.1016\/j.eururo.2014.11.039_bib0115","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jclinepi.2007.11.010","article-title":"Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry","volume":"61","author":"Peters","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1536867X0900900202","article-title":"Updated tests for small-study effects in meta-analyses","volume":"9","author":"Harbord","year":"2009","journal-title":"Stata J"},{"key":"10.1016\/j.eururo.2014.11.039_bib0125","doi-asserted-by":"crossref","first-page":"948","DOI":"10.2307\/2533848","article-title":"Assessing the sensitivity of regression results to unmeasured confounders in observational studies","volume":"54","author":"Lin","year":"1998","journal-title":"Biometrics"},{"key":"10.1016\/j.eururo.2014.11.039_bib0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/j.2517-6161.1983.tb01242.x","article-title":"Assessing sensitivity to an unobserved binary covariate in an observational study with binary outcome","volume":"45","author":"Rosenbaum","year":"1983","journal-title":"J R Stat Soc Ser B"},{"key":"10.1016\/j.eururo.2014.11.039_bib0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/EDE.0b013e3181f74493","article-title":"Bias formulas for sensitivity analysis of unmeasured confounding for general outcomes, treatments, and confounders","volume":"22","author":"VanderWeele","year":"2011","journal-title":"Epidemiology"},{"key":"10.1016\/j.eururo.2014.11.039_bib0140","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.CIR.59.1.8","article-title":"Diabetes and cardiovascular risk factors: the Framingham study","volume":"59","author":"Kannel","year":"1979","journal-title":"Circulation"},{"key":"10.1016\/j.eururo.2014.11.039_bib0145","unstructured":"Diabetes public health resource. Rate per 100 of civilian, noninstitutionalized population with diagnosed diabetes, by age, United States, 1980\u20132011. Centers for Disease Control and Prevention Web site. http:\/\/www.cdc.gov\/diabetes\/statistics\/prev\/national\/figbyage.htm."},{"key":"10.1016\/j.eururo.2014.11.039_bib0150","doi-asserted-by":"crossref","first-page":"96","DOI":"10.2105\/AJPH.2012.301091","article-title":"Smoking and risk of coronary heart disease in younger, middle-aged, and older adults","volume":"104","author":"Tolstrup","year":"2014","journal-title":"Am J Public Health"},{"key":"10.1016\/j.eururo.2014.11.039_bib0155","unstructured":"Smoking & tobacco use. Adult cigarette smoking in the United States: current estimates. Centers for Disease Control and Prevention Web site. http:\/\/www.cdc.gov\/tobacco\/data_statistics\/fact_sheets\/adult_data\/cig_smoking\/index.htm."},{"key":"10.1016\/j.eururo.2014.11.039_bib0160","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","article-title":"Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality","volume":"99","author":"Tsai","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.11.039_bib0165","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","article-title":"Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy","volume":"24","author":"Braga-Basaria","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0170","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/j.2047-2927.2013.00093.x","article-title":"Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for non-metastatic prostate cancer: implementation of standardized management guidelines","volume":"1","author":"Cheung","year":"2013","journal-title":"Andrology"},{"key":"10.1016\/j.eururo.2014.11.039_bib0175","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1464-410X.2011.10459.x","article-title":"Hormone therapy for prostate cancer and the risk of stroke: a 5-year follow-up study","volume":"109","author":"Chung","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.11.039_bib0180","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"D\u2019Amico","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0185","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2007.12.3752","article-title":"Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0190","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","article-title":"Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02","volume":"54","author":"Efstathiou","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0195","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1002\/cncr.26623","article-title":"Androgen deprivation and thromboembolic events in men with prostate cancer","volume":"118","author":"Ehdaie","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.11.039_bib0200","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2010.03.018","article-title":"Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external beam radiation therapy with and without adjuvant androgen deprivation therapy at the British Columbia Cancer Agency","volume":"80","author":"Kim","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.11.039_bib0205","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cncr.25597","article-title":"Coronary revascularization and mortality in men with congestive heart failure or prior myocardial infarction who receive androgen deprivation","volume":"117","author":"Nguyen","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.11.039_bib0210","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.ijrobp.2011.04.067","article-title":"Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction","volume":"82","author":"Nguyen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.11.039_bib0215","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","article-title":"Androgen deprivation therapy and cardiovascular risk","volume":"29","author":"Punnen","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0220","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1200\/JCO.2007.13.9881","article-title":"Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610","volume":"26","author":"Roach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0225","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ijc.26022","article-title":"Ischemic heart disease and stroke before and during endocrine treatment for prostate cancer in PCBaSe Sweden","volume":"130","author":"Robinson","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.11.039_bib0230","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/cncr.22933","article-title":"Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer","volume":"110","author":"Saigal","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2014.11.039_bib0235","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","article-title":"Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix","volume":"186","author":"Smith","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0240","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2013.05.044","article-title":"Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer","volume":"87","author":"Tendulkar","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2014.11.039_bib0245","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000334999","article-title":"Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term","volume":"82","author":"Wilcox","year":"2012","journal-title":"Oncology"},{"key":"10.1016\/j.eururo.2014.11.039_bib0250","first-page":"1518","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"104","author":"Keating","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.11.039_bib0255","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2826.2011.02119.x","article-title":"The heart: A novel gonadotrophin-releasing hormone target","volume":"23","author":"Dong","year":"2011","journal-title":"J Neuroendocrinol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0260","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3835(06)80010-8","article-title":"Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues","volume":"98","author":"Kakar","year":"1995","journal-title":"Cancer Lett"},{"key":"10.1016\/j.eururo.2014.11.039_bib0265","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1557988314522642","article-title":"The effect of testosterone on cardiovascular disease a critical review of the literature","volume":"8","author":"Su","year":"2014","journal-title":"Am J Mens Health"},{"key":"10.1016\/j.eururo.2014.11.039_bib0270","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/CS20020209","article-title":"Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia","volume":"104","author":"Dockery","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.eururo.2014.11.039_bib0275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1677\/joe.0.1780373","article-title":"Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability","volume":"178","author":"Malkin","year":"2003","journal-title":"J Endocrinol"},{"key":"10.1016\/j.eururo.2014.11.039_bib0280","first-page":"743","article-title":"Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor \u03b3-chain messenger ribonucleic acids that are regulated by GnRH in vitro 1","volume":"84","author":"Chen","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl","key":"10.1016\/j.eururo.2014.11.039_bib0285","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1194\/jlr.R800099-JLR200","article-title":"Molecular and cellular mechanisms of the thrombotic complications of atherosclerosis","volume":"50","author":"Libby","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.eururo.2014.11.039_bib0290","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0024-3205(98)00172-6","article-title":"The effect of LHRH and TRH on human interferon-gamma production in vivo and in vitro","volume":"62","author":"Grasso","year":"2014","journal-title":"Life Sci"},{"key":"10.1016\/j.eururo.2014.11.039_bib0295","series-title":"Fabry disease: perspective from 5 years of FOS","article-title":"Formal trials versus observational studies","author":"Thadhani","year":"2006"},{"key":"10.1016\/j.eururo.2014.11.039_bib0300","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.eururo.2012.04.035","article-title":"Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?","volume":"64","author":"Keating","year":"2013","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814012226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:29:29Z","timestamp":1717608569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814012226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0302283814012226"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.11.039","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 European Association of Urology. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}